Cohn Amy C, Guymer Robyn H
Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia.
Department of Ophthalmology, The Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Taiwan J Ophthalmol. 2024 Nov 6;14(4):464-472. doi: 10.4103/tjo.TJO-D-24-00065. eCollection 2024 Oct-Dec.
As we move toward an era in which there will be treatment options for geographic atrophy (GA) secondary to age-related macular degeneration, the need to accurately understand and interpret multimodal imaging (MMI) for the condition is paramount. This review discusses the evolution of MMI in GA and how it has led to a greater understanding of different phenotypes and risk factors for progression. These advancements have allowed novel imaging biomarkers to be used as end points in large interventional studies exploring new therapies for GA treatment. Due to differences in drug approval timing, ophthalmologists in some jurisdictions are already treating patients with complement inhibiting intravitreal therapies and using MMI to guide management. Cementing knowledge of how GA appears on MMI and evolves over time will be vital for best practice as these interventions become more widely available.
随着我们迈向一个针对年龄相关性黄斑变性继发的地图样萎缩（GA）将有治疗选择的时代，准确理解和解读该病症的多模态成像（MMI）的需求至关重要。本综述讨论了MMI在GA中的发展历程，以及它如何使人们对不同表型和疾病进展的风险因素有了更深入的了解。这些进展使得新型成像生物标志物能够用作大型干预性研究的终点，这些研究旨在探索GA治疗的新疗法。由于药物批准时间的差异，一些司法管辖区的眼科医生已经在用玻璃体内补体抑制疗法治疗患者，并使用MMI来指导治疗管理。随着这些干预措施越来越广泛地应用，巩固关于GA在MMI上的表现以及随时间如何演变的知识对于最佳实践至关重要。
